Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
202 hedge funds and large institutions have $3.04B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2015 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 78 increasing their positions, 50 reducing their positions, and 75 closing their positions.
70% more call options, than puts
Call options by funds: $115M | Put options by funds: $67.3M
56% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 50
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
11% more capital invested
Capital invested by funds: $2.74B → $3.04B (+$294M)
9% less funds holding
Funds holding: 223 → 202 (-21)
27% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 75
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$70.1M |
| 2 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$44.2M |
| 3 |
GAM
Gotham Asset Management
New York
|
+$40.4M |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$31.1M |
| 5 |
BC
Broadfin Capital
New York
|
+$28.5M |
Top Sellers
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$102M |
| 2 |
D.E. Shaw & Co
New York
|
-$46.6M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$41.8M |
| 4 |
HCM
Highline Capital Management
New York
|
-$40.9M |
| 5 |
MAI
Marble Arch Investments
New York
|
-$32M |
HZNP Hedge Fund Activity: Q4 2015 in Review
202 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2015, worth a combined $3.04B — up 11% from $2.74B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of HZNP and 55 opened new positions — a net loss of 20 holders — while 50 trimmed existing stakes and 78 added.
The largest buyer was Deerfield Management, adding an estimated $70.1M. The largest seller was Discovery Capital Management, exiting entirely with an estimated $102M sold.
- 202 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2015, down from 223 in Q3 2015.
- Funds reported $3.04B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2015, up 11% quarter-over-quarter.
- 55 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2015 and 75 closed out, a net change of -20 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2015 was Deerfield Management, an estimated $70.1M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2015 was Discovery Capital Management, an estimated $102M sold.
Based on aggregated 13F filings for Q4 2015.